Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07563881
PHASE3

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

Sponsor: Rapport Therapeutics Inc.

View on ClinicalTrials.gov

Summary

This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.

Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

333

Start Date

2026-05

Completion Date

2029-09

Last Updated

2026-05-04

Healthy Volunteers

No

Interventions

DRUG

RAP-219

RAP-219 high dose tablets administered orally daily

DRUG

RAP-219

RAP-219 medium dose tablets administered orally daily

OTHER

Placebo

Matching placebo tablets administered orally daily